18 hours Ago By ABMN Staff
KLP Kapitalforvaltning AS acquired a new stake in Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR – Free Report ) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 23,100 shares of the biotechnology company’s stock, valued at approximately $434,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. R Squared Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at about $38,000. Van ECK Associates Corp grew its position in Arrowhead Pharmaceuticals by 72.
3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 1,250 shares in the last quarter. KBC Group NV raised its stake in shares of Arrowhead Pharmaceuticals by 45.
9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter valued at approximately $149,000.
Finally, Envestnet Portfolio Solutions Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $190,000. Institutional investors and hedge funds own 62.
61% of the company’s stock. Arrowhead Pharmaceuticals Trading Down 11.4 % NASDAQ:ARWR opened at $10.
68 on Friday. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $10.
66 and a 52 week high of $30.41. The company has a quick ratio of 6.
09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.
The company has a market cap of $1.47 billion, a PE ratio of -2.07 and a beta of 0.
92. The business’s 50 day moving average is $17.31 and its two-hundred day moving average is $19.
32. Wall Street Analyst Weigh In A number of equities research analysts recently weighed in on ARWR shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.
00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. B. Riley reaffirmed a “buy” rating and set a $38.
00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. HC Wainwright reiterated a “buy” rating and issued a $80.
00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th.
Finally, Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company.
According to MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Hold” and an average price target of $41.44.
Get Our Latest Analysis on Arrowhead Pharmaceuticals Insider Activity In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 32,729 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.
82, for a total value of $648,688.78. Following the sale, the insider now directly owns 272,122 shares in the company, valued at approximately $5,393,458.
04. This trade represents a 10.74 % decrease in their ownership of the stock.
The transaction was disclosed in a filing with the SEC, which can be accessed through this link . Also, CEO Christopher Richard Anzalone sold 51,425 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $15.
07, for a total transaction of $774,974.75. Following the transaction, the chief executive officer now directly owns 4,062,377 shares of the company’s stock, valued at approximately $61,220,021.
39. This trade represents a 1.25 % decrease in their position.
The disclosure for this sale can be found here . In the last three months, insiders sold 274,797 shares of company stock valued at $4,830,279. Company insiders own 4.
30% of the company’s stock. About Arrowhead Pharmaceuticals ( Free Report ) Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Further Reading Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR – Free Report ).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
